CN102784247B - Chitosan oligosaccharide containing medicine composition with blood fat reducing function - Google Patents
Chitosan oligosaccharide containing medicine composition with blood fat reducing function Download PDFInfo
- Publication number
- CN102784247B CN102784247B CN201210311244.2A CN201210311244A CN102784247B CN 102784247 B CN102784247 B CN 102784247B CN 201210311244 A CN201210311244 A CN 201210311244A CN 102784247 B CN102784247 B CN 102784247B
- Authority
- CN
- China
- Prior art keywords
- oligochitosan
- extract
- folium ginkgo
- vitis viniferae
- semen vitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention discloses a chitosan oligosaccharide containing medicine composition with a blood fat reducing function, and relates to the technical field of medicines. Active components of the medicine composition include chitosan oligosaccharide, ginkgo biloba extract and grape pip extract, and the weight ratio of the chitosan oligosaccharide to the ginkgo biloba extract to the grape pip extract is 1:0.1-1:1-10. All the active components of the medicine composition are natural products, have fewer side effects, are safe and reliable, and have remarkable blood fat regulating and slimming functions.
Description
Technical field
The present invention relates to medical technical field, be specifically related to a kind of pharmaceutical composition that hypolipemic function contains oligochitosan that has.
Background technology
Lipid metabolism or running make one or more lipids of blood plasma higher than being normally called hyperlipidemia extremely.Hyperlipidemia is a kind of systemic disease, refers to that T-CHOL in blood (TC) and/or triglyceride (TG) are too high or HDL-C (HDL-C) is too low, and modern medicine is referred to as dyslipidemia.This disease to the infringement of health be concealment, gradually, carrying out property and general.Its direct infringement is to accelerate systemic atherosclerosis, because the vitals of whole body all will rely on tremulous pulse blood supply, oxygen supply, once tremulous pulse is stopped up by atheromatous plaque, will cause serious consequence.The renal failure that arteriosclerosis causes etc., all closely related with hyperlipidemia.Research datas show in a large number, and hyperlipidemia is apoplexy, coronary heart disease, myocardial infarction, cardiac sudden death is independent and important risk factor.Therefore, people start the emphasis using the exploitation of blood lipid regulation medicine as prevention and cure of cardiovascular disease.
At present, the medicine for the treatment of hyperlipemia mainly contains: (1) HMG-CoA reductase inhibitor (Statins); (2) phenoxy acetic acid class fat regulation medicine (the special class of shellfish); (3) nicotinic acid class fat regulation medicine; (4) bile acid chelating agent; (5) cholesterol absorption inhibitor; (6) cholesterol synthetic inhibitor; (7) n-3 fatty acid, n-3(W-3) long-chain polyunsaturated fatty acid; (8) probucol.Although these Western medicine can reduce blood lipid level, its toxic and side effects is self-evident, such as the most frequently used statins can cause rhabdomyolysis.
Summary of the invention
In view of the deficiencies in the prior art, the object of the invention is to, by the Chinese medicine extract of the oligochitosan having no side effect and medicine-food two-purpose and consumption screens and prescription, provides and has hypolipemic function containing the pharmaceutical composition of oligochitosan.Make us unforeseeable, pharmaceutical composition of the present invention not only can concertedness reduce T-CHOL (TC), the level of low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG), but also there is the effect that weight reducing is lost weight.
In order to realize object of the present invention, inventor studies by lot of experiments, has finally obtained following technical scheme:
The present invention is a kind of has hypolipemic function containing the pharmaceutical composition of oligochitosan, and its active component is comprised of oligochitosan, Folium Ginkgo extract and Semen Vitis viniferae extract.
Described oligochitosan is that the degree of polymerization is the pharmaceutical grade oligochitosan of 2-50.Described oligochitosan is to be prepared from according to following technique: by 5%(w/v) concentration chitosan is dissolved in to 1%-5%(v/v) in acetum, add the chitosanase that is equivalent to chitosan weight 5%, intensification is stirred to reaction at 30 ℃, after 60 hours, start ultrafiltration, the part that is less than molecular cut off 300 sees through filter membrane, the molecule that is greater than molecular cut off 6000 returns to reactor and continues degraded, ultrafiltrate is again by nanofiltration device, permeation parts is water, acetic acid and small molecular sugar, to be condensed to not be that 50% degree of polymerization is 2-50 oligochitosan to permeation parts, then through 75% ethanol precipitation, filter, supernatant is dry through spraying, the pharmaceutical grade oligochitosan that the formation degree of polymerization is 2-50, the oligochitosan content that wherein degree of polymerization is 4-30 is 67%.
Described Folium Ginkgo extract is prepared from as follows: the 75%-95% alcoholic solution heating and refluxing extraction that dry Folium Ginkgo is doubly measured with 8-10 2-4 time, each 1-1.5h, filter, residue medicinal residues after filtrate discards, add Folium Ginkgo weight 10-15 water heating and refluxing extraction doubly 2-4 time, each 1-1.5h, refilter, filtrate is concentrated into paste, and lyophilization evacuation, obtains Folium Ginkgo extract.
Described Semen Vitis viniferae extract is prepared from as follows: after Semen Vitis viniferae is cleaned to pulverizing, soak 0.2-0.8 hour, lasting 0.5-1 hour is heated to seethe with excitement, cooled and filtered, filtering residue adds water post-heating to boiling again and continues 0.5-1 hour, refilter, twice filtrate is merged, filter, the concentrated solution that while being concentrated into 65 ℃, relative density is 1.05-1.10, adds appropriate ethanol and makes to reach 70%-75%(v/v containing alcohol amount), 0 ℃ of cold preservation 18-30 hour, filter, filtrate recycling ethanol is also concentrated into paste, and lyophilization evacuation, obtains Semen Vitis viniferae extract.
Further preferably, described in there is hypolipemic function containing the pharmaceutical composition of oligochitosan, wherein the weight ratio of oligochitosan, Folium Ginkgo extract and Semen Vitis viniferae extract is 1:(0.1-1): (1-10).
Again further preferably, described in there is hypolipemic function containing the pharmaceutical composition of oligochitosan, wherein the weight ratio of oligochitosan, Folium Ginkgo extract and Semen Vitis viniferae extract is 1:(0.2-0.5): (2-5).
Again further preferably, described in there is hypolipemic function containing the pharmaceutical composition of oligochitosan, wherein the weight ratio of oligochitosan, Folium Ginkgo extract and Semen Vitis viniferae extract is 1:0.3:3.
Compared with prior art, the related active component of pharmaceutical composition containing oligochitosan the present invention relates to is natural product, side effect is little, safe and reliable, there is significant tune blood fat and weight reducing effect of weight reducing simultaneously, specifically by embodiments of the invention 2(oligochitosan, Folium Ginkgo extract and Semen Vitis viniferae extract coupling, the impact of obese type hyperlipidemia mice tested) can find out:
(1) the 2nd week from administration starts to weigh every 2 weeks, and result shows, since the 6th week, test III group and model group or test I group compared significant difference (
p< 0.05); In addition, in the time of the 8th week, test III group compare with model group or test I group and there is utmost point significant difference (
p< 0.01), test III group compared with test II group significant difference (
p< 0.05).These result of the tests show for obesity mice, to have good effect of weight reducing after oligochitosan, Folium Ginkgo extract and Semen Vitis viniferae extract use in conjunction.
(2), after administration finishes, detect serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG).Result shows, aspect serum total cholesterol, triglyceride levels, test III group compare with model group, test I group and test II group and there is significant difference (
p< 0.05) or utmost point significant difference (
p< 0.01); Aspect low-density lipoprotein cholesterol level, test III group compare with model group and there is significant difference (
p< 0.05), compare with test I group or test II group and there is no significant difference (
p> 0.05).These result of the tests show for obese type hyperlipidemia mice, to have after oligochitosan, Folium Ginkgo extract and Semen Vitis viniferae extract use in conjunction the effect of good concertedness blood fat reducing.
The specific embodiment
Form is described in further detail foregoing of the present invention again by the following examples, but this should be interpreted as to the scope of the above-mentioned theme of the present invention only limits to following embodiment, all technology realizing based on foregoing of the present invention all belong to scope of the present invention.
the preparation of embodiment 1 capsule
(1) by 5%(w/v) concentration chitosan is dissolved in to 1%-5%(v/v) in acetum, add the chitosanase that is equivalent to chitosan weight 5%, intensification is stirred to reaction at 30 ℃, after 60 hours, start ultrafiltration, the part that is less than molecular cut off 300 sees through filter membrane, the molecule that is greater than molecular cut off 6000 returns to reactor and continues degraded, ultrafiltrate is again by nanofiltration device, permeation parts is water, acetic acid and small molecular sugar, to be condensed to not be that 50% degree of polymerization is 2-50 oligochitosan to permeation parts, then through 75% ethanol precipitation, filter, supernatant is dry through spraying, the pharmaceutical grade oligochitosan that the formation degree of polymerization is 2-50, the oligochitosan content that wherein degree of polymerization is 4-30 is 67%.
(2) by 85% alcoholic solution heating and refluxing extraction of 8 times of amounts 3 times for dry Folium Ginkgo, each 1.5h, filter, residue medicinal residues after filtrate discards, add the water heating and refluxing extraction 3 times of 12 times of Folium Ginkgo weight, each 1.5h, refilter, filtrate is concentrated into paste, and lyophilization evacuation, obtains Folium Ginkgo extract.
(3) by soaking 0.5 hour after the clean pulverizing of Semen Vitis viniferae, be heated to boiling and continue 1 hour, cooled and filtered, filtering residue adds water post-heating to boiling again and continues 1 hour, refilters, and twice filtrate is merged, filter, the concentrated solution that while being concentrated into 65 ℃, relative density is 1.05-1.10, adds appropriate ethanol and makes to reach 75%(v/v containing alcohol amount), 0 ℃ of cold preservation 24 hours, filter, filtrate recycling ethanol is also concentrated into paste, and lyophilization evacuation, obtains Semen Vitis viniferae extract.
(4) by the oligochitosan of above-mentioned preparation, Folium Ginkgo extract and Semen Vitis viniferae extract by weight for 1:(0.1-1): (1-10) mix filled capsules shell after taking.Or, by the oligochitosan of above-mentioned preparation, Folium Ginkgo extract and Semen Vitis viniferae extract by weight for 1:(0.1-1): (1-10) mix after taking, add pharmaceutical grade adjuvant, technique is prepared granule routinely, filled capsules shell.
embodiment 2 oligochitosans, Folium Ginkgo extract and the Semen Vitis viniferae extract coupling impact test on obese type hyperlipidemia mice
4 week age KM mice, male and female half and half, feed and take high lipid food (formula of high lipid food is casein 1kg, Cys 15g, maltodextrin 0.75kg, sucrose 0.35kg, cellulose 0.25kg, soybean oil 0.15kg, Adeps Sus domestica 1.25kg).Raise after 10 weeks, superseded body weight is less than the mice of 60g, the administration of then dividing into groups, and packet domain administering mode is in Table 1.
Table 1 is respectively organized gavage tested material and the dosage of mice
Note: oligochitosan, Folium Ginkgo extract and Semen Vitis viniferae extract are all prepared from according to the technique of the embodiment of the present invention 1.
During administration, still feed with high lipid food, every day, gavage twice, respectively in 9:00,21:00 gavage, and continuous 8 weeks.
The 2nd week from administration starts to weigh every 2 weeks, and result shows, since the 6th week, test III group and model group or test I group compared significant difference (
p< 0.05); In addition, in the time of the 8th week, test III group compare with model group or test I group and there is utmost point significant difference (
p< 0.01), test III group compared with test II group significant difference (
p< 0.05).These result of the tests show for obesity mice, to have good effect of weight reducing after oligochitosan, Folium Ginkgo extract and Semen Vitis viniferae extract use in conjunction.Experimental result refers to table 2.
Impact (the unit: g) of each group of table 2 compound recipe on Mouse Weight
| Group | Administration the 2nd week | Administration the 4th week | Administration the 6th week | Administration the 8th week |
| Model control group | ?70.5±8.1 | 73.6±8.5 | 74.2±7.4 | 75.4±9.0 |
| Test I group | ?71.0±8.3 | 71.5±6.6 | 73.1±7.0 | 74.9±7.4 |
| Test II group | 69.2±6.9 | 68.5±7.9 | 72.9±8.1 | 73.5±6.8 |
| Test III group | 68.9±7.0 | 66.9±7.2 | ?65.5±7.0 *￥ | 66.2±5.4 **￥￥▼ |
*with model group comparison,
p< 0.05;
*with model group comparison,
p< 0.01;
$with the comparison of test I group group,
p< 0.05;
$$with the comparison of test I group group,
p< 0.01;
▼with the comparison of test II group group,
p< 0.05;
▼ ▼with the comparison of test II group group,
p< 0.01.
After administration finishes, detect serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG).Result shows, aspect serum total cholesterol, triglyceride levels, test III group compare with model group, test I group and test II group and there is significant difference (
p< 0.05) or utmost point significant difference (
p< 0.01); Aspect low-density lipoprotein cholesterol level, test III group compare with model group and there is significant difference (
p< 0.05), compare with test I group or test II group and there is no significant difference (
p> 0.05).These result of the tests show for obese type hyperlipidemia mice, to have after oligochitosan, Folium Ginkgo extract and Semen Vitis viniferae extract use in conjunction the effect of good concertedness blood fat reducing.Experimental result refers to table 3.
Each group of table 3 compound recipe is on the impact of lipid in mouse blood (mmol/L)
| Group | TC | TG | LDL-C |
| Model control group | 2.92±0.34 | 1.85±0.29 | 0.66±0.17 |
| Test I group | 2.76±0.25 * | 1.83±0.41 | 0.60±0.15 |
| Test II group | 2.98±0.39 | 1.72±0.36 | 0.58±0.09 |
| Test III group | ? 2.54±0.35 *￥▼▼ | 1.35±0.26 **￥￥▼ | 0.55±0.10 * |
*with model group comparison,
p< 0.05;
*with model group comparison,
p< 0.01;
$with the comparison of test I group group,
p< 0.05;
$$with the comparison of test I group group,
p< 0.01;
▼with the comparison of test II group group,
p< 0.05;
▼ ▼with the comparison of test II group group,
p< 0.01.
Claims (3)
1. one kind has hypolipemic function containing the pharmaceutical composition of oligochitosan, it is characterized in that: the active component of described pharmaceutical composition is comprised of oligochitosan, Folium Ginkgo extract and Semen Vitis viniferae extract, the weight ratio of described oligochitosan, Folium Ginkgo extract and Semen Vitis viniferae extract is 1:0.1-1:1-10;
Wherein, described oligochitosan is the pharmaceutical grade oligochitosan of degree of polymerization 2-50;
Described Folium Ginkgo extract, be prepared from as follows: the 75%-95% alcoholic solution heating and refluxing extraction that dry Folium Ginkgo is doubly measured with 8-10 2-4 time, each 1-1.5h, filters the residue medicinal residues after filtrate discards, add Folium Ginkgo weight 10-15 water heating and refluxing extraction doubly 2-4 time, each 1-1.5h, refilters, and filtrate is concentrated into paste, lyophilization evacuation, obtains Folium Ginkgo extract;
Described Semen Vitis viniferae extract, be prepared from as follows: after Semen Vitis viniferae is cleaned to pulverizing, soak 0.2-0.8 hour, lasting 0.5-1 hour is heated to seethe with excitement, cooled and filtered, filtering residue adds water post-heating to boiling again and continues 0.5-1 hour, refilter, twice filtrate is merged, filter the concentrated solution that while being concentrated into 65 ℃, relative density is 1.05-1.10, adding appropriate ethanol makes to reach 70%-75% containing alcohol amount volume ratio, 0 ℃ of cold preservation 18-30 hour, filters, and filtrate recycling ethanol is also concentrated into paste, lyophilization evacuation, obtains Semen Vitis viniferae extract.
2. there is according to claim 1 hypolipemic function containing the pharmaceutical composition of oligochitosan, it is characterized in that: the weight ratio of described oligochitosan, Folium Ginkgo extract and Semen Vitis viniferae extract is 1:0.2-0.5:2-5.
3. according to thering is the pharmaceutical composition of hypolipemic function containing oligochitosan described in claim 1 or 2, it is characterized in that: the weight ratio of described oligochitosan, Folium Ginkgo extract and Semen Vitis viniferae extract is 1:0.3:3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210311244.2A CN102784247B (en) | 2012-08-29 | 2012-08-29 | Chitosan oligosaccharide containing medicine composition with blood fat reducing function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210311244.2A CN102784247B (en) | 2012-08-29 | 2012-08-29 | Chitosan oligosaccharide containing medicine composition with blood fat reducing function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102784247A CN102784247A (en) | 2012-11-21 |
| CN102784247B true CN102784247B (en) | 2014-02-05 |
Family
ID=47149966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210311244.2A Active CN102784247B (en) | 2012-08-29 | 2012-08-29 | Chitosan oligosaccharide containing medicine composition with blood fat reducing function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102784247B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103462025A (en) * | 2013-09-29 | 2013-12-25 | 厦门中药厂有限公司 | Health food assisting in reducing blood fat and preparation method and application thereof |
| CN105395827A (en) * | 2015-11-30 | 2016-03-16 | 山东卫康生物医药科技有限公司 | Method for preparing composition with function of reducing blood fat |
| CN105381202A (en) * | 2015-11-30 | 2016-03-09 | 山东卫康生物医药科技有限公司 | Composition with blood fat reducing function |
| CN108144034A (en) * | 2018-02-13 | 2018-06-12 | 桂林三金大健康产业有限公司 | A kind of reducing blood lipid and/or Chinese medicine composition and its application for improving memory |
-
2012
- 2012-08-29 CN CN201210311244.2A patent/CN102784247B/en active Active
Non-Patent Citations (6)
| Title |
|---|
| 吴宗群等.银杏叶提取物的药理作用研究.《中国药师》.2006,第9卷(第12期),1150-1152. |
| 壳寡糖降血脂作用及与RAP表达相关性研究;胡迎青;《中国临床医学》;20071231;第14卷(第6期);749-752 * |
| 孙来华.葡萄籽功能成分及其应用.《食品研究与开发》.2011,第32卷(第7期),184-188. |
| 胡迎青.壳寡糖降血脂作用及与RAP表达相关性研究.《中国临床医学》.2007,第14卷(第6期),749-752. |
| 葡萄籽功能成分及其应用;孙来华;《食品研究与开发》;20110731;第32卷(第7期);184-188 * |
| 银杏叶提取物的药理作用研究;吴宗群等;《中国药师》;20061231;第9卷(第12期);1150-1152 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102784247A (en) | 2012-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhu et al. | Comparative effects of hawthorn (Crataegus pinnatifida Bunge) pectin and pectin hydrolyzates on the cholesterol homeostasis of hamsters fed high-cholesterol diets | |
| Shen et al. | Policosanol: Extraction and biological functions | |
| EP1902722B1 (en) | Agent for elevating adiponectin concentration | |
| KR102110040B1 (en) | Composition for preventing and treating of obesity or metabolic disease comprising Elaeagnus umbellata extracts | |
| CN102784247B (en) | Chitosan oligosaccharide containing medicine composition with blood fat reducing function | |
| JP2007520418A (en) | Ginseng preparation using vinegar and method for producing the same | |
| JP2015532917A (en) | New extracts of artichoke, coffea and olive for treating metabolic syndrome | |
| KR20150055876A (en) | Composition for reducing body-fat and weight | |
| CN102068494B (en) | Health-care capsules with treatment effect on chemical liver injury and preparation method thereof | |
| CN113061195A (en) | Compound polysaccharide with blood fat reducing effect and preparation method and application thereof | |
| JPH08225453A (en) | Lipoprotein (a) depressor, cholesterol depressor and medicine containing the same | |
| KR101729003B1 (en) | Composition For Preventing or Treating Gout Containing Extracts or Fermentation Metabolites of Dendropanax morbiferus | |
| JP6042800B2 (en) | Tomatoside A extraction method | |
| JP5506229B2 (en) | Metabolic syndrome improvement or prevention agent | |
| CN104288566B (en) | Traditional Chinese medicine composition for reducing cholesterol and/or reducing blood lipids as well as preparation method and application of traditional Chinese medicine composition | |
| KR20090109679A (en) | Method of preparing catechin-rich green tea and its product | |
| KR102648340B1 (en) | Composition for hepatoprotective activity comprising Turmeric extract solution and Rice Soybean extract | |
| JP2011012021A (en) | Blood sugar-controlling composition | |
| KR101393607B1 (en) | Composition containing fermented rice bran for the prevention and treatment of non-alcoholic fatty liver | |
| JP2006022082A (en) | Lipid metabolism improver | |
| CN105412613A (en) | Composition for Alzheimer's disease and processing method of composition | |
| JP2007246429A (en) | Lipase inhibitor, and food and drink | |
| CN104013696A (en) | Plant medicine composition for preventing and treating metabolic syndrome and application thereof | |
| JP2008214246A (en) | Age production inhibitor and method for producing the same | |
| JP2009132634A (en) | Antiobestic agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |